Managing adverse effects and complications in completing treatment for hepatitis C virus infection. (Q33404375)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23154251%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

Managing adverse effects and complications in completing treatment for hepatitis C virus infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23154251%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

Kenneth E Sherman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23154251%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

1 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23154251%20AND%20SRC:MED&resulttype=core&format=json

Topics in antiviral medicine

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23154251%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23154251%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23154251%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

125-128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23154251%20AND%20SRC:MED&resulttype=core&format=json

Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection

18 February 2020

cites work

1 reference

12 December 2020

Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals

1 reference

12 December 2020

Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin

1 reference

12 December 2020

Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.

1 reference

12 December 2020

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

12 December 2020

Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach

1 reference

12 December 2020

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.

1 reference

12 December 2020

Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.

1 reference

12 December 2020

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

12 December 2020

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

12 December 2020

Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial

1 reference

12 December 2020

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23154251%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

PubMed publication ID

23154251

1 reference